

INNOVATION

The New Currency of Competition



REPUBLIC OF INNOVATION

Opening remarks

Medtech

«State of the Nation»

Dr. Benoit Dubuis



REPUBLIC OF INNOVATION

MEDTECH

«State of the Nation»

- A changing environment
- Information leveraging technologies
- Our contribution



REPUBLIC OF INNOVATION

MEDTECH

«State of the Nation»

- A changing environment
- Information leveraging technologies
- Our contribution



REPUBLIC OF INNOVATION

Towards a NEW NORMAL !



"NEW NORMAL" ?

World economy returns to pre-crisis rate of growth

OR

Growth stays at a permanently lower rate
(investment, employment, growth...)


6

25.04.2013 | MTI, Keynote B. Dubuis



6

Engaging diverse stakeholders...




7

25.04.2013 | MTI, Keynote B. Dubuis




7

...facing new risks from an increasing diverse range of sources




25.04.2013 | MTI, Keynote B. Dubuis

Innovation capital raised in US and Europe ... still low!




25.04.2013 | MTI, Keynote B. Dubuis

Venture investment by round ... are favoring "de-risked" later-stage companies



25.04.2013 | MTI, Keynote B. Dubuis

European medtech financing by year



25.04.2013 | MTI, Keynote B. Dubuis


Top 10 European venture rounds, 2011-H1 2012

Company	Region	Product type (Euronext)	Series raised (€/\$Mn)	Quarter	Round type
Agendia	Netherlands	Non imaging diagnostics	68	Q2 2012	Late stage
Idigaptic	Israel	Therapeutic devices (oncology)	31	Q2 2012	Late stage
Oxford Immunotec	United Kingdom	Non imaging diagnostics	28	Q1 2012	Late stage
Atlas Genetics	United Kingdom	Non imaging diagnostics	27	Q3 2011	Late stage
Amplitude	France	Therapeutic devices (orthopedic)	24	Q1 2012	Late stage
Corvus	Germany	Non imaging diagnostics	23	Q4 2011	Early stage
Totix Technology	Sweden	Other	21	Q1 2012	Late stage
BrainGate	Israel	Therapeutic devices (neurology)	20	Q3 2011	Late stage
MyoPower Medical Technologies	Switzerland	Therapeutic devices (cardiovascular)	18	Q3 2011	Early stage
Cordicell	Sweden	Therapeutic devices (cardiovascular)	18	Q3 2011	Early stage

Source: Ernst & Young, BMO Capital Markets, Dow Jones VentureSource and Medtronic

25.04.2013 | MTI, Keynote B. Dubuis

Capital raised by leading European countries, July 2011-June 2012



25.04.2013 | MTI, Keynote B. Dubuis

Innovation at Risk ?




25.04.2013 | MTI, Keynote B. Dubuis

Eclon

15

M&As in the US and Europe (US\$bn)



Source: Ernst & Young, Capital IQ and Thomson ONE

25.04.2013 | MTI, Keynote B. Dubuis

Eclon

16

US and European M&As by segment

Segment	July 2007 - June 2011			July 2011 - June 2012		
	Number of deals	Value (US\$bn)	% of total deal value	Number of deals	Value (US\$bn)	% of total deal value
Therapeutic devices	344	\$128,525	68%	126	\$15,778	53%
Ophthalmic	33	\$58,295	30%	10	\$187	1%
Orthopedic	54	\$27,670	15%	17	\$370	1%
Cardiovascular	72	\$17,120	9%	18	\$4,700	16%
Respiratory	16	\$5,907	3%	5	\$59	0%
Non-disease specific	48	\$2,178	1%	32	\$1,512	5%
Multiple	11	\$3,472	2%	11	\$1,859	6%
Hematology/renal	13	\$3,054	2%	5	\$72	0%
Wound care	21	\$2,891	2%	7	\$6,495	22%
Oncology	10	\$881	0%	2	\$535	1%
All others	66	\$8,977	5%	19	\$182	1%
Research and other equipment	75	\$38,409	20%	19	\$1,068	4%
Non-imaging diagnostics	113	\$13,140	7%	46	\$10,881	36%
Other	43	\$7,136	4%	21	\$479	2%
Imaging	50	\$2,571	1%	21	\$1,571	5%

Source: Ernst & Young, Capital IQ and Thomson ONE

Table only shows deals where values were publicly disclosed


Figures may be inconsistent due to rounding

25.04.2013 | MTI, Keynote B. Dubuis

Eclon

17

The shift to patient-empowering, information-leveraging technologies



25.04.2013 | MTI, Keynote B. Dubuis

Eclon


18

MEDTECH "State of the Nation"

- A changing environment
- Information leveraging technologies
- Our contribution

REPUBLIC OF
INNOVATION

Towards an integrated health system

Evolution of Molecular Medicine and Information-Based Medicine:
Foundation for Rational Care and Personalized Medicine

25.04.2013 | MTI, Keynote B. Dubuis

Eclon

20

Interdisciplinarity (science driven)

25.04.2013 | MTI, Keynote B. Dubuis

Interdisciplinarity (science driven)

25.04.2013 | MTI, Keynote B. Dubuis

Confluence of Technology / tools / Knowledge

25.04.2013 | MTI, Keynote B. Dubuis

Healthcare is becoming...digitized

- Smart cards with electronic health records & sequenced DNA
- Consumer driven personal health planning
 - PHR
 - Microsoft -HealthVault™
 - Google Health
 - WebMD
 - Revolution Health
 - WalMart/Dell/eclinicalWorks

Note: Europe / Asia may be faster, more integrated than US & Europe

25.04.2013 | MTI, Keynote B. Dubuis

Remote Patient Monitoring

25.04.2013 | MTI, Keynote B. Dubuis

Personalized Medicine


Putting the patient at the center of their health system

Source: Henry Kautz, Department of Computer Science, Rochester University

25.04.2013 | MTI, Keynote B. Dubuis

Smart Sensing

- Non-invasive wearable sensors
- Personal biosensors
- Environmental sensors
- New data streams + machine learning = "New vital signs"



25.04.2013 | MTI, Keynote B. Dubuis

Source: Henry Kautz, Department of Computer Science, Rochester University

Intelligent Information Management

- Longitudinal data
 - Personal baseline
 - Detect trends & deviations from norm
- Personal health records
 - Privacy
 - Sharing
 - Anonymous aggregation
- Patient-centered decision support



Source: Henry Kautz, Department of Computer Science, Rochester University

25.04.2013 | MTI, Keynote B. Dubuis

Source: Burrill

Effective Interfaces

- Multimodal
 - GUI, touch, gesture, speech, ...
- Mobile
 - Portable, networked, wearable
- Intuitive
 - Easy to learn, use, maintain
- Adaptive
- Proactive



Source: Henry Kautz, Department of Computer Science, Rochester University

25.04.2013 | MTI, Keynote B. Dubuis

Source: Burrill

Smart-Phone Makers Call the Doctor



Rapid Secure Communication with Doctors

- Relay health (McKesson)
- Minute clinic
- FitNet

25.04.2013 | MTI, Keynote B. Dubuis

Source: Burrill

Ten Targets for Wireless Medicine

Disease	No. Affected	Wireless Solutions
Alzheimer's	5M	Vital signs, location, activity, balance
Asthma	23M	RR, FEV1, Air quality, oximetry, pollen
Breast Cancer	3M	Ultrasound self-exam → Web
COPD*	10M	RR, FEV1, Air quality, oximetry
Depression	21M	Med Compliance, Activity, Communication
Diabetes	24M	Glucose, Hemoglobin A1C
Heart Failure	5M	Cardiac pressures, weight, BP, fluid status
Hypertension	74M	Continuous BP, Med compliance
Obesity	80M	Smart scales, Glucose, Caloric in/out,
Activity		
Sleep Disorders	40M	Sleep phases, quality, apnea, vital signs

* Chronic obstructive pulmonary disease


31

Source: Burrill

25.04.2013 | MTI, Keynote B. Dubuis

Source: Burrill

A New Healthcare Ecosystem Arising From Technology and Market Convergence



Diagnostics (Dx), imaging (Ix), therapeutics (Rx), devices and healthcare information (Hlx)

Molecular diagnostics (MDx)

(EMR) Electronic Medical Record (PMR) Private Medical Record

25.04.2013 | MTI, Keynote B. Dubuis


Source: Burrill

MEDTECH "State of the Nation"

- A changing environment
- Information leveraging technologies
- Our contribution



Interdisciplinarity (science driven)



25.04.2013 | MTI, Keynote B. Dubuis




39

A unique hub for Medtech/Biotech R&D in Europe



25.04.2013 | MTI, Keynote B. Dubuis


40




Confluence of Technology / tools / Knowledge




Switzerland is a global hotspot for medtech



Switzerland shows a high trade balance surplus for finished medtech products



The Swiss medtech industry is embedded in a unique ecosystem



Switzerland is an attractive manufacturing site


No.	Company ¹⁾	Sub-section of market	Head-quarters	Employees in Switzerland	Global sales [CHF m]	1 year global sales growth [%]	R&D expenses [CHF m]	R&D/sales [%]
1	JM Medical	Orthopedics, neurosurgery, cardiology, surgery	USA	4,500	25,570	2	1,751	6.8
2	Roche Diagnostics	In-vitro diagnostics	CH	2,110	9,700	6	900	9.2
3	Medtronic	Implants to treat cardiac rhythm, cardiovascular and neurological diseases, treatments for spinal disorders ²⁾	USA	1,200	15,787	4	1,400	9
4	Sonova	Hearing systems	CH	1,200	1,620	0.2	105	7.2
5	Zimmer	Orthopedics	USA	950	4,370	5	218	5
6	B. Braun	Orthopedics, hospital aids and medical devices	DE	940	5,539	4	216	4
7	Upomed	Injection systems	CH	800	249	-5	25	10
8	Straumann	Dental implants	CH	830	694	6	39	6
9	Stryker	Orthopedics	USA	650	7,200	0	385	6
				Σ 13,180		Σ 2.5		Σ 7

1) Approximately, manufacturers only, figures for reporting year 2011/12, exchange rates used: 0.9693 USD/CHF
2) The authors believe that among the 10 biggest medtech employers Hamilton Medical should also be listed. However, Hamilton Medical is not willing to communicate any company data
3) Swiss made devices only

Source: Annual company reports and press offices


25.04.2013 | MTI, Keynote B. Dubuis | 48

Switzerland has one of the highest densities of medtech companies




SMEs form the backbone of the Swiss medtech industry

DISTRIBUTION OF COMPANIES BY NO. OF EMPLOYEES



- The SMTI is largely composed of SMEs (<250 employees)
- Compared with the whole industrial sector in Switzerland the SMTI has significantly fewer micro-companies: 52% versus 79%

DISTRIBUTION OF EMPLOYEES BY CATEGORY




- Most medtech employees are working for manufacturing companies
- Service providers and suppliers are mainly small and micro companies

25.04.2013 | MTI, Keynote B. Dubuis

The SMTI has a strong home market

HEALTHCARE EXPENDITURE PER CAPITA [current USD]




Source: Medical Cluster, Medtech Switzerland, IMS Consulting Group, CTI

25.04.2013 | MTI, Keynote B. Dubuis

SMTI manufacturers heavily collaborate with multiple stakeholders


COLLABORATION PARTNER OF MANUFACTURERS



n = 69, multiple answers possible

25.04.2013 | MTI, Keynote B. Dubuis

SMTI firms have a robust young product portfolio

AGE OF PRODUCT PORTFOLIO BY COMPANY SIZE⁽¹⁾

Company size: micro companies = 0-49 employees, small = 50-99, medium = 100-249, large = >250

- Only manufacturers
- In proportion of their product portfolio
- Necessary threshold for innovating portfolio with true innovation (see SMTI 2010)

25.04.2013 | MTI, Keynote B. Dubuis

All SMTI's firms suffer from a tougher market environment

RANKING OF CHALLENGES [in %]⁽¹⁾

n range = 202 - 309; multiple answers possible

- Challenge is of "high relevance" or "average relevance" to SMTI companies
- Price pressure, intensified competition, and lack of resources/management capacities

25.04.2013 | MTI, Keynote B. Dubuis

PRINCIPLES FOR FUTURE SUCCESS

Innovate in new ways

- Improve the efficacy of the innovation process to keep a competitive advantage
- Adapt to the needs of new and emerging stakeholders
- Provide data evidence that your solution is better than current, existing products
- Hire regulatory experts to navigate into an increasingly demanding regulatory frameworks
- Drive actively the consolidation process in the industry by joining forces with other medtech companies

57

25.04.2013 | MTI, Keynote B. Dubuis

